{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T19:11:31Z","timestamp":1791141091161,"version":"4.1.0"},"reference-count":83,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T00:00:00Z","timestamp":1779062400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:00:00Z","timestamp":1783555200000},"content-version":"vor","delay-in-days":52,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Imaging"],"DOI":"10.1186\/s40644-026-01035-7","type":"journal-article","created":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T04:25:55Z","timestamp":1779078355000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["The evolving PI-RADS paradigm"],"prefix":"10.1186","volume":"26","author":[{"given":"Andrea","family":"Ponsiglione","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivo G.","family":"Schoots","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anwar R.","family":"Padhani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,18]]},"reference":[{"key":"1035_CR1","doi-asserted-by":"publisher","first-page":"e222990","DOI":"10.1148\/radiol.222990","volume":"307","author":"AR Padhani","year":"2023","unstructured":"Padhani AR, Schoots IG. Imaging-based Diagnostic and Therapeutic Strategies for Prostate Cancer in the Coming Decades. Radiol. 2023;307:e222990. . https:\/\/doi.org\/10.1148\/radiol.222990","journal-title":"Radiol [Internet]"},{"key":"1035_CR2","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.eururo.2024.08.022","volume":"87","author":"V Kasivisvanathan","year":"2025","unstructured":"Kasivisvanathan V, Wai-Shun Chan V, Clement KD, Levis B, Ng A, Asif A, et al. VISION: An Individual Patient Data Meta-analysis of Randomised Trials Comparing Magnetic Resonance Imaging Targeted Biopsy with Standard Transrectal Ultrasound Guided Biopsy in the Detection of Prostate Cancer. Eur Urol. 2025;87:512\u201323. https:\/\/doi.org\/10.1016\/j.eururo.2024.08.022.","journal-title":"Eur Urol"},{"key":"1035_CR3","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/j.eururo.2020.03.048","volume":"78","author":"NJ Sathianathen","year":"2020","unstructured":"Sathianathen NJ, Omer A, Harriss E, Davies L, Kasivisvanathan V, Punwani S, et al. Negative Predictive Value of Multiparametric Magnetic Resonance Imaging in the Detection of Clinically Significant Prostate Cancer in the Prostate Imaging Reporting and Data System Era: A Systematic Review and Meta-analysis. Eur Urol. 2020;78:402\u201314. https:\/\/doi.org\/10.1016\/j.eururo.2020.03.048.","journal-title":"Eur Urol"},{"key":"1035_CR4","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.eururo.2024.03.027","volume":"86","author":"P Cornford","year":"2024","unstructured":"Cornford P, van den Bergh RCN, Briers E, Van den Broeck T, Brunckhorst O, Darraugh J, et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer\u20142024 Update. Part I: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol. 2024;86:148\u201363. https:\/\/doi.org\/10.1016\/j.eururo.2024.03.027.","journal-title":"Eur Urol"},{"key":"1035_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2015.08.052","author":"JC Weinreb","year":"2016","unstructured":"Weinreb JC, Barentsz JO, Choyke PL, Cornud F, Haider MA, Macura KJ, et al. PI-RADS Prostate Imaging \u2013 Reporting and Data System: 2015, Version 2. Eur Urol. 2016;69:16\u201340. https:\/\/doi.org\/10.1016\/j.eururo.2015.08.052"},{"key":"1035_CR6","author":"B Turkbey","year":"2019","unstructured":"Turkbey B, Rosenkrantz AB, Haider MA, Padhani AR, Villeirs G, Macura KJ, et al. Prostate imaging reporting and data system version 2.1: 2019 update of prostate imaging reporting and data system version 2. Eur Urol. 2019;76:340-351."},{"key":"1035_CR7","doi-asserted-by":"publisher","first-page":"103","DOI":"10.2214\/ajr.166.1.8571856","volume":"166","author":"JC Presti","year":"1996","unstructured":"Presti JC, Hricak H, Narayan PA, Shinohara K, White S, Carroll PR. Local staging of prostatic carcinoma: comparison of transrectal sonography and endorectal MR imaging. Am J Roentgenol. 1996;166:103\u20138. https:\/\/doi.org\/10.2214\/ajr.166.1.8571856.","journal-title":"Am J Roentgenol"},{"key":"1035_CR8","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1007\/s00330-011-2377-y","volume":"22","author":"JO Barentsz","year":"2012","unstructured":"Barentsz JO, Richenberg J, Clements R, Choyke P, Verma S, Villeirs G, et al. ESUR prostate MR guidelines 2012. Eur Radiol. 2012;22:746\u201357. https:\/\/doi.org\/10.1007\/s00330-011-2377-y.","journal-title":"Eur Radiol"},{"key":"1035_CR9","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.eururo.2010.12.009","volume":"59","author":"L Dickinson","year":"2011","unstructured":"Dickinson L, Ahmed HU, Allen C, Barentsz JO, Carey B, Futterer JJ, et al. Magnetic resonance imaging for the detection, localisation, and characterisation of prostate cancer: recommendations from a European consensus meeting. Eur Urol. 2011;59:477\u201394. https:\/\/doi.org\/10.1016\/j.eururo.2010.12.009.","journal-title":"Eur Urol"},{"key":"1035_CR10","doi-asserted-by":"publisher","DOI":"10.1102\/1470-7330.2011.9007","author":"AR Padhani","year":"2011","unstructured":"Padhani AR. Integrating multiparametric prostate MRI into clinical practice. Cancer Imaging. 2011. https:\/\/doi.org\/10.1102\/1470-7330.2011.9007. 11 Spec No A:S27-37."},{"key":"1035_CR11","doi-asserted-by":"publisher","first-page":"7985","DOI":"10.1007\/s00330-024-10883-5","volume":"34","author":"A Ponsiglione","year":"2024","unstructured":"Ponsiglione A, McGuire W, Petralia G, Fennessy M, Benkert T, Ponsiglione AM, et al. Image quality of whole-body diffusion MR images comparing deep-learning accelerated and conventional sequences. Eur Radiol. 2024;34:7985\u201393. https:\/\/doi.org\/10.1007\/s00330-024-10883-5.","journal-title":"Eur Radiol"},{"key":"1035_CR12","doi-asserted-by":"publisher","first-page":"505","DOI":"10.4274\/dir.2024.242926","volume":"31","author":"M Kantarc\u0131","year":"2025","unstructured":"Kantarc\u0131 M, Ayd\u0131n S, O\u011ful H, K\u0131z\u0131lg\u00f6z V. New imaging techniques and trends in radiology. Diagn Interv Radiol. 2025;31:505\u201317. . https:\/\/doi.org\/10.4274\/dir.2024.242926","journal-title":"Diagn Interv Radiol [Internet]"},{"key":"1035_CR13","doi-asserted-by":"publisher","first-page":"4252","DOI":"10.1007\/s00261-020-02487-6","volume":"45","author":"M Coskun","year":"2020","unstructured":"Coskun M, Mehralivand S, Shih JH, Merino MJ, Wood BJ, Pinto PA, et al. Impact of bowel preparation with Fleet\u2019s\u2122 enema on prostate MRI quality. Abdom Radiol. 2020;45:4252\u20139. https:\/\/doi.org\/10.1007\/s00261-020-02487-6.","journal-title":"Abdom Radiol"},{"key":"1035_CR14","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s00330-017-4940-7","volume":"28","author":"T Ullrich","year":"2018","unstructured":"Ullrich T, Quentin M, Schmaltz AK, Arsov C, Rubbert C, Blondin D, et al. Hyoscine butylbromide significantly decreases motion artefacts and allows better delineation of anatomic structures in mp-MRI of the prostate. Eur Radiol. 2018;28:17\u201323. https:\/\/doi.org\/10.1007\/s00330-017-4940-7.","journal-title":"Eur Radiol"},{"key":"1035_CR15","doi-asserted-by":"publisher","first-page":"6454","DOI":"10.1007\/s00330-025-11618-w","volume":"35","author":"G Agrotis","year":"2025","unstructured":"Agrotis G, Pooch EP, Marsitopoulos K, Vlychou M, Benndorf M, Beets-Tan RGH, et al. Detection rates for prostate cancer using PI-RADS 2.1 upgrading rules in transition zone lesions align with risk assessment categories: a systematic review and meta-analysis. Eur Radiol. 2025;35:6454\u201365. https:\/\/doi.org\/10.1007\/s00330-025-11618-w.","journal-title":"Eur Radiol"},{"key":"1035_CR16","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1056\/NEJMoa1801993","volume":"378","author":"V Kasivisvanathan","year":"2018","unstructured":"Kasivisvanathan V, Rannikko AS, Borghi M, Panebianco V, Mynderse LA, Vaarala MH, et al. MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis. N Engl J Med. 2018;378:1767\u201377. https:\/\/doi.org\/10.1056\/NEJMoa1801993.","journal-title":"N Engl J Med"},{"key":"1035_CR17","doi-asserted-by":"publisher","unstructured":"Oerther B, Nedelcu A, Engel H, Schmucker C, Schwarzer G, Brugger T, et al. Update on PI-RADS version 2.1 diagnostic performance benchmarks for prostate MRI: systematic review and meta-analysis. Radiology. 2024;312. https:\/\/doi.org\/10.1148\/radiol.233337.","DOI":"10.1148\/radiol.233337"},{"key":"1035_CR18","doi-asserted-by":"publisher","DOI":"10.2214\/AJR.25.33583","author":"A Nedelcu","year":"2025","unstructured":"Nedelcu A, Oerther B, Benkendorff A, Dieckbreder S, Schwarzer G, Agrotis G, et al. PI-RADS Version 2.1 for Prostate MRI Interpretation: Associations of Study Quality and Cancer Detection Metrics\u2014A Systematic Review and Meta-Analysis. Am J Roentgenol. 2025. https:\/\/doi.org\/10.2214\/AJR.25.33583.","journal-title":"Am J Roentgenol"},{"key":"1035_CR19","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1111\/bju.15277","volume":"127","author":"IG Schoots","year":"2021","unstructured":"Schoots IG, Padhani AR. Risk-adapted biopsy decision based on prostate magnetic resonance imaging and prostate\u2010specific antigen density for enhanced biopsy avoidance in first prostate cancer diagnostic evaluation. BJU Int. 2021;127:175\u20138. https:\/\/doi.org\/10.1111\/bju.15277.","journal-title":"BJU Int"},{"key":"1035_CR20","doi-asserted-by":"publisher","unstructured":"Tan N, Pollock JR, Margolis DJA, Padhani AR, Tempany C, Woo S, et al. Management of patients with a negative multiparametric prostate MRI examination: AJR Expert panel narrative review. AJR Am J Roentgenol. 2024;223. https:\/\/doi.org\/10.2214\/AJR.23.29969.","DOI":"10.2214\/AJR.23.29969"},{"key":"1035_CR21","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1097\/JU.0000000000001832","volume":"206","author":"AG Raman","year":"2021","unstructured":"Raman AG, Sarma KV, Raman SS, Priester AM, Mirak SA, Riskin-Jones HH, et al. Optimizing Spatial Biopsy Sampling for the Detection of Prostate Cancer. J Urol. 2021;206:595\u2013603. https:\/\/doi.org\/10.1097\/JU.0000000000001832.","journal-title":"J Urol"},{"key":"1035_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2021.03.004","author":"M Ahdoot","year":"2022","unstructured":"Ahdoot M, Lebastchi AH, Long L, Wilbur AR, Gomella PT, Mehralivand S, et al. Using prostate imaging-reporting and data system (pi-rads) scores to select an optimal prostate biopsy method: a secondary analysis of the trio study. Eur Urol Oncol. 2022;5:176\u2013186. https:\/\/doi.org\/10.1016\/j.euo.2021.03.004"},{"key":"1035_CR23","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1007\/s00261-023-03929-7","volume":"48","author":"R Nicola","year":"2023","unstructured":"Nicola R, Bittencourt LK. PI-RADS 3 lesions: a critical review and discussion of how to improve management. Abdom Radiol. 2023;48:2401\u20135. https:\/\/doi.org\/10.1007\/s00261-023-03929-7.","journal-title":"Abdom Radiol"},{"key":"1035_CR24","doi-asserted-by":"publisher","unstructured":"Schoots IG. MRI in early prostate cancer detection: how to manage indeterminate or equivocal PI-RADS 3 lesions? Transl Androl Urol. 2018;7:70\u201382. https:\/\/doi.org\/10.21037\/tau.2017.12.31.","DOI":"10.21037\/tau.2017.12.31"},{"key":"1035_CR25","doi-asserted-by":"publisher","unstructured":"Luzzago S, Colombo A, Mistretta FA, Alessi S, Di Trapani E, Summers PE, et al. Multiparametric MRI-based 5-year risk prediction model for biochemical recurrence of prostate cancer after radical prostatectomy. Radiology. 2023;309. https:\/\/doi.org\/10.1148\/radiol.223349.","DOI":"10.1148\/radiol.223349"},{"key":"1035_CR26","doi-asserted-by":"publisher","unstructured":"Shadbahr T, Pylv\u00e4l\u00e4inen J, Eineluoto J, Moro A, Kerro O, Kentt\u00e4mies A et al. PI-RADS v2 is a strong prognostic marker for adverse outcomes in prostate cancer. 2025. https:\/\/doi.org\/10.1101\/2025.03.20.25324337.","DOI":"10.1101\/2025.03.20.25324337"},{"key":"1035_CR27","doi-asserted-by":"publisher","first-page":"139","DOI":"10.4274\/dir.2023.232414","volume":"30","author":"\u00d6 \u00d6nder","year":"2024","unstructured":"\u00d6nder \u00d6, Ayva M, Yara\u015f\u0131r Y, G\u00fcrler V, Yaz\u0131c\u0131 MS, Akdo\u011fan B, et al. Long-term follow-up results of multiparametric prostate MRI and the prognostic value of PI-RADS: a single-center retrospective cohort study. Diagn Interventional Radiol. 2024;30:139\u201351. https:\/\/doi.org\/10.4274\/dir.2023.232414.","journal-title":"Diagn Interventional Radiol"},{"key":"1035_CR28","doi-asserted-by":"publisher","first-page":"162","DOI":"10.62347\/BODM5001","volume":"12","author":"J Nwanze","year":"2024","unstructured":"Nwanze J. Prognostic significance of the PI-RADS score in men with prostate cancer undergoing radical prostatectomy. Am J Clin Exp Urol. 2024;12:162\u201372. https:\/\/doi.org\/10.62347\/BODM5001.","journal-title":"Am J Clin Exp Urol"},{"key":"1035_CR29","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.juro.2010.08.082","volume":"185","author":"T Wolters","year":"2011","unstructured":"Wolters T, Roobol MJ, van Leeuwen PJ, van den Bergh RCN, Hoedemaeker RF, van Leenders GJLH, et al. A critical analysis of the tumor volume threshold for clinically insignificant prostate cancer using a data set of a randomized screening trial. J Urol. 2011;185:121\u20135. https:\/\/doi.org\/10.1016\/j.juro.2010.08.082.","journal-title":"J Urol"},{"key":"1035_CR30","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1111\/j.1464-410X.2006.06660.x","volume":"99","author":"MH Winkler","year":"2007","unstructured":"Winkler MH, Livni N, Mannion EM, Hrouda D, Christmas T. Characteristics of incidental prostatic adenocarcinoma in contemporary radical cystoprostatectomy specimens. BJU Int. 2007;99:554\u20138. https:\/\/doi.org\/10.1111\/j.1464-410X.2006.06660.x.","journal-title":"BJU Int"},{"key":"1035_CR31","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1002\/1097-0142(19930201)71:3+<933::aid-cncr2820711408>3.0.co;2-l","volume":"71","author":"TA Stamey","year":"1993","unstructured":"Stamey TA, Freiha FS, McNeal JE, Redwine EA, Whittemore AS, Schmid HP. Localized prostate cancer. Relationship of tumor volume to clinical significance for treatment of prostate cancer. Cancer. 1993;71:933\u20138. https:\/\/doi.org\/10.1002\/1097-0142(19930201)71:3%2B%253C933::aid-cncr2820711408%253E3.0.co;2-l.","journal-title":"Cancer"},{"key":"1035_CR32","doi-asserted-by":"publisher","first-page":"21501","DOI":"10.1038\/s41598-022-26065-6","volume":"12","author":"D Singh","year":"2022","unstructured":"Singh D, Das CJ, Kumar V, Singh A, Mehndiratta A. Quantification of prostate tumour diameter and volume from MR images using 3D ellipsoid model and its impact on PI-RADS v2.1 assessment. Sci Rep. 2022;12:21501. https:\/\/doi.org\/10.1038\/s41598-022-26065-6.","journal-title":"Sci Rep"},{"key":"1035_CR33","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.eururo.2024.09.035","volume":"87","author":"JJ Twilt","year":"2025","unstructured":"Twilt JJ, Saha A, Bosma JS, van Ginneken B, Bjartell A, Padhani AR, et al. Evaluating Biparametric Versus Multiparametric Magnetic Resonance Imaging for Diagnosing Clinically Significant Prostate Cancer: An International, Paired, Noninferiority, Confirmatory Observer Study. Eur Urol. 2025;87:240\u201350. https:\/\/doi.org\/10.1016\/j.eururo.2024.09.035.","journal-title":"Eur Urol"},{"key":"1035_CR34","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1002\/bco2.415","volume":"5","author":"EV Li","year":"2024","unstructured":"Li EV, Kumar SK, Aguiar JA, Siddiqui MR, Neill C, Sun Z, et al. Utility of dynamic contrast enhancement for clinically significant prostate cancer detection. BJUI Compass. 2024;5:865\u201373. https:\/\/doi.org\/10.1002\/bco2.415.","journal-title":"BJUI Compass"},{"key":"1035_CR35","doi-asserted-by":"publisher","first-page":"5828","DOI":"10.1007\/s00330-023-09605-0","volume":"33","author":"E Messina","year":"2023","unstructured":"Messina E, Pecoraro M, Laschena L, Bicchetti M, Proietti F, Ciardi A, et al. Low cancer yield in PI-RADS 3 upgraded to 4 by dynamic contrast-enhanced MRI: is it time to reconsider scoring categorization? Eur Radiol. 2023;33:5828\u201339. https:\/\/doi.org\/10.1007\/s00330-023-09605-0.","journal-title":"Eur Radiol"},{"key":"1035_CR36","doi-asserted-by":"publisher","DOI":"10.2214\/AJR.20.24495","author":"AS Purysko","year":"2021","unstructured":"Purysko AS, Baroni RH, Giganti F, Costa D, Renard-Penna R, Kim CK, et al. PI-RADS Version 2.1: A Critical review, from the ajr special series on radiology reporting and data systems. AJR Am J Roentgenol. 2021;216:20\u201332. https:\/\/doi.org\/10.2214\/AJR.20.24495"},{"key":"1035_CR37","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1055\/s-0043-1778636","volume":"07","author":"A Pandey","year":"2024","unstructured":"Pandey A, Ghosh S, Prajapati P, Nakrour N, Harisinghani M. Pearls and Pitfalls in Applying PI-RADS 2.1. J Gastrointest Abdom Radiol. 2024;07:183\u2013202. https:\/\/doi.org\/10.1055\/s-0043-1778636.","journal-title":"J Gastrointest Abdom Radiol"},{"key":"1035_CR38","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1148\/rg.2016150226","volume":"36","author":"Y Li","year":"2016","unstructured":"Li Y, Mongan J, Behr SC, Sud S, Coakley FV, Simko J, et al. Beyond Prostate Adenocarcinoma: Expanding the Differential Diagnosis in Prostate Pathologic Conditions. Radiographics. 2016;36:1055\u201375. https:\/\/doi.org\/10.1148\/rg.2016150226.","journal-title":"Radiographics"},{"key":"1035_CR39","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1007\/s00330-025-12066-2","volume":"36","author":"A Ponsiglione","year":"2025","unstructured":"Ponsiglione A, Cimadamore A, Girometti R. Unmasking unconventional prostate cancer histologies: A real diagnostic challenge? Eur Radiol. 2025;36:30\u20132. https:\/\/doi.org\/10.1007\/s00330-025-12066-2.","journal-title":"Eur Radiol"},{"key":"1035_CR40","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s13244-017-0578-x","volume":"9","author":"V Panebianco","year":"2018","unstructured":"Panebianco V, Giganti F, Kitzing YX, Cornud F, Campa R, De Rubeis G, et al. An update of pitfalls in prostate mpMRI: a practical approach through the lens of PI-RADS v. 2 guidelines. Insights Imaging. 2018;9:87\u2013101. https:\/\/doi.org\/10.1007\/s13244-017-0578-x.","journal-title":"Insights Imaging"},{"key":"1035_CR41","doi-asserted-by":"publisher","first-page":"110984","DOI":"10.1016\/j.ejrad.2023.110984","volume":"166","author":"A Ponsiglione","year":"2023","unstructured":"Ponsiglione A, Campo I, Sachs C, Sofia C, \u00c1lvarez-Hornia P\u00e9rez E, Ciabattoni R, et al. Extraprostatic incidental findings on prostate mpMRI: A pictorial review from the ESUR junior network. Eur J Radiol. 2023;166:110984. https:\/\/doi.org\/10.1016\/j.ejrad.2023.110984.","journal-title":"Eur J Radiol"},{"key":"1035_CR42","doi-asserted-by":"publisher","first-page":"110849","DOI":"10.1016\/j.ejrad.2023.110849","volume":"164","author":"G Brembilla","year":"2023","unstructured":"Brembilla G, Lavalle S, Parry T, Cosenza M, Russo T, Mazzone E, et al. Impact of prostate imaging quality (PI-QUAL) score on the detection of clinically significant prostate cancer at biopsy. Eur J Radiol. 2023;164:110849. https:\/\/doi.org\/10.1016\/j.ejrad.2023.110849.","journal-title":"Eur J Radiol"},{"key":"1035_CR43","doi-asserted-by":"publisher","first-page":"6171","DOI":"10.1007\/s00330-025-11547-8","volume":"35","author":"R Girometti","year":"2025","unstructured":"Girometti R, Peruzzi V, Clauser P, P\u00f6tsch N, De Martino M, Isola M, et al. Diffusion levels for quantitative assessment of the apparent diffusion coefficient value in prostate MRI: a proof-of-concept bicentric study. Eur Radiol. 2025;35:6171\u201382. https:\/\/doi.org\/10.1007\/s00330-025-11547-8.","journal-title":"Eur Radiol"},{"key":"1035_CR44","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1007\/s10334-021-00932-1","volume":"35","author":"AV Malagi","year":"2021","unstructured":"Malagi AV, Netaji A, Kumar V, Baidya Kayal E, Khare K, Das CJ, et al. IVIM\u2013DKI for differentiation between prostate cancer and benign prostatic hyperplasia: comparison of 1.5 T vs. 3 T MRI. Magnetic Resonance Materials in Physics. Biology Med. 2021;35:609\u201320. https:\/\/doi.org\/10.1007\/s10334-021-00932-1.","journal-title":"Biology Med"},{"key":"1035_CR45","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1002\/jmri.27191","volume":"53","author":"N Schieda","year":"2021","unstructured":"Schieda N, Lim CS, Zabihollahy F, Abreu-Gomez J, Krishna S, Woo S, et al. Quantitative Prostate MRI. J Magn Reson Imaging. 2021;53:1632\u201345. https:\/\/doi.org\/10.1002\/jmri.27191","journal-title":"J Magn Reson Imaging [Internet]"},{"key":"1035_CR46","doi-asserted-by":"publisher","first-page":"3383","DOI":"10.1007\/s00330-019-06654-2","volume":"30","author":"G Brembilla","year":"2020","unstructured":"Brembilla G, Dell\u2019Oglio P, Stabile A, Damascelli A, Brunetti L, Ravelli S, et al. Interreader variability in prostate MRI reporting using Prostate Imaging Reporting and Data System version 2.1. Eur Radiol. 2020;30:3383\u201392. https:\/\/doi.org\/10.1007\/s00330-019-06654-2","journal-title":"Eur Radiol [Internet]"},{"key":"1035_CR47","doi-asserted-by":"publisher","unstructured":"Smani S, Jalfon M, Sundaresan V, Lokeshwar SD, Nguyen J, Halstuch D et al. Inter-reader reliability and diagnostic accuracy of PI-RADS scoring between academic and community care networks: How wide is the gap? Urol Oncol. 2025;43:396e1-396.e7. https:\/\/doi.org\/10.1016\/j.urolonc.2024.10.002.","DOI":"10.1016\/j.urolonc.2024.10.002"},{"key":"1035_CR48","doi-asserted-by":"publisher","unstructured":"Saha A, Bosma JS, Twilt JJ, Ng ABCD, Asif A, Magudia K, et al. Scaling artificial intelligence for prostate cancer detection on MRI towards organized screening and primary diagnosis in a global, multiethnic population (study protocol). 2025. https:\/\/doi.org\/10.48550\/arXiv.2508.03762","DOI":"10.48550\/arXiv.2508.03762"},{"key":"1035_CR49","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.2214\/AJR.20.23883","volume":"216","author":"C Wei","year":"2021","unstructured":"Wei C, Zhang Y, Pan P, Chen T, Yu H, Dai G, et al. Diagnostic Accuracy and Interobserver Agreement of PI-RADS Version 2 and Version 2.1 for the Detection of Transition Zone Prostate Cancers. Am J Roentgenol. 2021;216:1247\u201356. https:\/\/doi.org\/10.2214\/AJR.20.23883.","journal-title":"Am J Roentgenol"},{"key":"1035_CR50","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1148\/radiol.2020190646","volume":"296","author":"AC Westphalen","year":"2020","unstructured":"Westphalen AC, McCulloch CE, Anaokar JM, Arora S, Barashi NS, Barentsz JO, et al. Variability of the Positive Predictive Value of PI-RADS for Prostate MRI across 26 Centers: Experience of the Society of Abdominal Radiology Prostate Cancer Disease-focused Panel. Radiology. 2020;296:76\u201384. https:\/\/doi.org\/10.1148\/radiol.2020190646.","journal-title":"Radiology"},{"key":"1035_CR51","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.ejrad.2017.02.029","volume":"90","author":"I Caglic","year":"2017","unstructured":"Caglic I, Hansen NL, Slough RA, Patterson AJ, Barrett T. Evaluating the effect of rectal distension on prostate multiparametric MRI image quality. Eur J Radiol. 2017;90:174\u201380. https:\/\/doi.org\/10.1016\/j.ejrad.2017.02.029.","journal-title":"Eur J Radiol"},{"key":"1035_CR52","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1001\/jama.2025.13722","volume":"334","author":"ABCD Ng","year":"2025","unstructured":"Ng ABCD, Asif A, Agarwal R, Panebianco V, Girometti R, Ghai S, et al. Biparametric vs Multiparametric MRI for Prostate Cancer Diagnosis: The PRIME Diagnostic Clinical Trial. JAMA. 2025;334:1170\u201379. https:\/\/doi.org\/10.1001\/jama.2025.13722","journal-title":"JAMA"},{"key":"1035_CR53","doi-asserted-by":"publisher","first-page":"3","DOI":"10.2214\/AJR.20.24268","volume":"216","author":"IG Schoots","year":"2021","unstructured":"Schoots IG, Barentsz JO, Bittencourt LK, Haider MA, Macura KJ, Margolis DJA, et al. PI-RADS Committee Position on MRI Without Contrast Medium in Biopsy-Naive Men With Suspected Prostate Cancer: Narrative Review. Am J Roentgenol. 2021;216:3\u201319. https:\/\/doi.org\/10.2214\/AJR.20.24268","journal-title":"Am J Roentgenol [Internet]"},{"key":"1035_CR54","doi-asserted-by":"publisher","unstructured":"Lowrance W, Dreicer R, Jarrard DF, Scarpato KR, Kim SK, Kirkby E, et al. Updates to advanced prostate cancer: AUA\/SUO Guideline (2023). J Urol. 2023;209:1082\u201390. https:\/\/doi.org\/10.1097\/JU.0000000000003452.","DOI":"10.1097\/JU.0000000000003452"},{"key":"1035_CR55","doi-asserted-by":"publisher","first-page":"469","DOI":"10.6004\/jnccn.2025.0052","volume":"23","author":"DE Spratt","year":"2025","unstructured":"Spratt DE, Srinivas S, Adra N, Ahmed B, An Y, Bitting R, et al. Prostate Cancer, Version 3.2026, NCCN Clinical Practice Guidelines In Oncology. J Natl Compr Canc Netw. 2025;23:469\u201393. https:\/\/doi.org\/10.6004\/jnccn.2025.0052.","journal-title":"J Natl Compr Canc Netw"},{"key":"1035_CR56","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1016\/S1470-2045(24)00220-1","volume":"25","author":"A Saha","year":"2024","unstructured":"Saha A, Bosma JS, Twilt JJ, van Ginneken B, Bjartell A, Padhani AR, et al. Artificial intelligence and radiologists in prostate cancer detection on MRI (PI-CAI): an international, paired, non-inferiority, confirmatory study. Lancet Oncol. 2024;25:879\u201387. https:\/\/doi.org\/10.1016\/S1470-2045(24)00220-1.","journal-title":"Lancet Oncol"},{"key":"1035_CR57","doi-asserted-by":"publisher","unstructured":"Rodrigues AC, de Almeida JG, Rodrigues N, Moreno R, Castro Verde AS, Mascarenhas Gaiv\u00e3o A, et al. Improving clinically significant prostate cancer detection with a multimodal machine learning approach: a large-scale multicenter study. Radiol Imaging Cancer. 2025;7. https:\/\/doi.org\/10.1148\/rycan.240507.","DOI":"10.1148\/rycan.240507"},{"key":"1035_CR58","doi-asserted-by":"publisher","DOI":"10.1038\/s41391-025-01053-9","author":"X-R Xie","year":"2025","unstructured":"Xie X-R, Hou Y, Shan S, Zhi R, Wu C-J, Xia Y-F, et al. AI-aided diagnostic performance for prostate MRI: systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 2025. https:\/\/doi.org\/10.1038\/s41391-025-01053-9.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"1035_CR59","doi-asserted-by":"publisher","first-page":"11583","DOI":"10.1038\/s41467-025-66593-z","volume":"16","author":"H Wu","year":"2025","unstructured":"Wu H, Liu F, Yang Q, Chen H, Wang Y, Yang X, et al. Automated MRI system for clinically significant prostate cancer detection development validation and real-world implementation. Nat Commun. 2025;16:11583. https:\/\/doi.org\/10.1038\/s41467-025-66593-z.","journal-title":"Nat Commun"},{"key":"1035_CR60","doi-asserted-by":"publisher","unstructured":"Gelikman DG, Yilmaz EC, Harmon SA, Huang EP, An JY, Azamat S, et al. Evaluating artificial intelligence\u2013assisted prostate biparametric MRI interpretation: an international multireader study. Am J Roentgenol. 2025;225. https:\/\/doi.org\/10.2214\/AJR.24.32399.","DOI":"10.2214\/AJR.24.32399"},{"key":"1035_CR61","doi-asserted-by":"publisher","first-page":"5695","DOI":"10.1007\/s00330-025-11498-0","volume":"35","author":"AR Padhani","year":"2025","unstructured":"Padhani AR, Papanikolaou N. AI and human interactions in prostate cancer diagnosis using MRI. Eur Radiol. 2025;35:5695\u2013700. https:\/\/doi.org\/10.1007\/s00330-025-11498-0.","journal-title":"Eur Radiol"},{"key":"1035_CR62","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s41747-026-00695-1","volume":"10","author":"A Ponsiglione","year":"2026","unstructured":"Ponsiglione A, Di Costanzo G, Ponsiglione AM, Riccio C, Rinaldo A, Tucci AG, et al. Concurrent AI-human interaction in prostate cancer MRI interpretation: More hype than help? Eur Radiol Exp. 2026;10:35. https:\/\/doi.org\/10.1186\/s41747-026-00695-1.","journal-title":"Eur Radiol Exp"},{"key":"1035_CR63","doi-asserted-by":"publisher","unstructured":"Turkbey B, Huisman H, Fedorov A, Macura KJ, Margolis DJ, Panebianco V, et al. Requirements for AI development and reporting for MRI prostate cancer detection in biopsy-naive men: PI-RADS Steering Committee, version 1.0. Radiology. 2025;315. https:\/\/doi.org\/10.1148\/radiol.240140.","DOI":"10.1148\/radiol.240140"},{"key":"1035_CR64","doi-asserted-by":"publisher","first-page":"284","DOI":"10.3390\/jpm15070284","volume":"15","author":"S Ursprung","year":"2025","unstructured":"Ursprung S, Agrotis G, van Houdt PJ, ter Beek LC, Boellaard TN, Beets-Tan RGH, et al. Prostate MRI Using Deep Learning Reconstruction in Response to Cancer Screening Demands\u2014A Systematic Review and Meta-Analysis. J Pers Med. 2025;15:284. https:\/\/doi.org\/10.3390\/jpm15070284.","journal-title":"J Pers Med"},{"key":"1035_CR65","doi-asserted-by":"publisher","unstructured":"Bischoff LM, Peeters JM, Weinhold L, Krausewitz P, Ellinger J, Katemann C, et al. Deep learning super-resolution reconstruction for fast and motion-robust T2-weighted prostate MRI. Radiology. 2023;308. https:\/\/doi.org\/10.1148\/radiol.230427.","DOI":"10.1148\/radiol.230427"},{"key":"1035_CR66","doi-asserted-by":"publisher","first-page":"e2432588","DOI":"10.2214\/AJR.24.32588","volume":"225","author":"IG Schoots","year":"2025","unstructured":"Schoots IG, Haider MA, Punwani S, Padhani AR. MRI in Prostate Cancer Screening: A Review and Recommendations, From the AJR Special Series on Screening. AJR Am J Roentgenol [Internet]. 2025;225:e2432588. https:\/\/doi.org\/10.2214\/AJR.24.32588.","journal-title":"AJR Am J Roentgenol [Internet]"},{"key":"1035_CR67","doi-asserted-by":"publisher","first-page":"7481","DOI":"10.1007\/s00330-024-10792-7","volume":"34","author":"A Ponsiglione","year":"2024","unstructured":"Ponsiglione A, Brembilla G, Cuocolo R, Gutierrez P, Moreira AS, Pecoraro M, et al. ESR Essentials: using the right scoring system in prostate MRI\u2014practice recommendations by ESUR. Eur Radiol. 2024;34:7481\u201391. https:\/\/doi.org\/10.1007\/s00330-024-10792-7.","journal-title":"Eur Radiol"},{"key":"1035_CR68","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2024.03.014","author":"C Englman","year":"2024","unstructured":"Englman C, Maffei D, Allen C, Kirkham A, Albertsen P, Kasivisvanathan V, et al. PRECISE Version 2: Updated Recommendations for Reporting Prostate Magnetic Resonance Imaging in Patients on Active Surveillance for Prostate Cancer. Eur Urol https:\/\/doi.org\/10.1016\/j.eururo.2024.03.014","journal-title":"Eur Urol [Internet]"},{"key":"1035_CR69","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1016\/j.euo.2021.01.003","volume":"4","author":"V Panebianco","year":"2021","unstructured":"Panebianco V, Villeirs G, Weinreb JC, Turkbey BI, Margolis DJ, Richenberg J, et al. Prostate Magnetic Resonance Imaging for Local Recurrence Reporting (PI-RR): International Consensus -based Guidelines on Multiparametric Magnetic Resonance Imaging for Prostate Cancer Recurrence after Radiation Therapy and Radical Prostatectomy. Eur Urol Oncol. 2021;4:868\u201376. https:\/\/doi.org\/10.1016\/j.euo.2021.01.003.","journal-title":"Eur Urol Oncol"},{"key":"1035_CR70","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/j.euo.2023.04.007","volume":"6","author":"F Giganti","year":"2023","unstructured":"Giganti F, Dickinson L, Orczyk C, Haider A, Freeman A, Emberton M, et al. Prostate Imaging after Focal Ablation (PI-FAB): A Proposal for a Scoring System for Multiparametric MRI of the Prostate After Focal Therapy. Eur Urol Oncol. 2023;6:629\u201334. https:\/\/doi.org\/10.1016\/j.euo.2023.04.007.","journal-title":"Eur Urol Oncol"},{"key":"1035_CR71","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.eururo.2024.02.001","volume":"85","author":"A Light","year":"2024","unstructured":"Light A, Mayor N, Cullen E, Kirkham A, Padhani AR, Arya M, et al. The Transatlantic Recommendations for Prostate Gland Evaluation with Magnetic Resonance Imaging After Focal Therapy (TARGET): A Systematic Review and International Consensus Recommendations. Eur Urol. 2024;85:466\u201382. https:\/\/doi.org\/10.1016\/j.eururo.2024.02.001.","journal-title":"Eur Urol"},{"key":"1035_CR72","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-024-10795-4","author":"M de Rooij","year":"2024","unstructured":"de Rooij M, Allen C, Twilt JJ, Thijssen LCP, Asbach P, Barrett T, et al. PI-QUAL version 2: an update of a standardised scoring system for the assessment of image quality of prostate MRI. Eur Radiol [Internet]. 2024. https:\/\/doi.org\/10.1007\/s00330-024-10795-4.","journal-title":"Eur Radiol [Internet]"},{"key":"1035_CR73","doi-asserted-by":"publisher","first-page":"110973","DOI":"10.1016\/j.ejrad.2023.110973","volume":"166","author":"A Ponsiglione","year":"2023","unstructured":"Ponsiglione A, Stanzione A, Califano G, De Giorgi M, Coll\u00e0 Ruvolo C, D\u2019Iglio I, et al. MR image quality in local staging of prostate cancer: Role of PI-QUAL in the detection of extraprostatic extension. Eur J Radiol. 2023;166:110973. https:\/\/doi.org\/10.1016\/j.ejrad.2023.110973.","journal-title":"Eur J Radiol"},{"key":"1035_CR74","doi-asserted-by":"publisher","first-page":"111716","DOI":"10.1016\/j.ejrad.2024.111716","volume":"181","author":"A Ponsiglione","year":"2024","unstructured":"Ponsiglione A, Cereser L, Spina E, Mannacio L, Negroni D, Russo L, et al. PI-QUAL version 2: A Multi-Reader reproducibility study on multiparametric MRI from a tertiary referral center. Eur J Radiol. 2024;181:111716. https:\/\/doi.org\/10.1016\/j.ejrad.2024.111716.","journal-title":"Eur J Radiol"},{"key":"1035_CR75","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-024-10845-x","author":"A Ponsiglione","year":"2024","unstructured":"Ponsiglione A, Girometti R. PI-QUAL version 2: the radiologist's perspective. Eur Radiol. 2024;34:7065\u201367. https:\/\/doi.org\/10.1007\/s00330-024-10845-x","journal-title":"Eur Radiol [Internet]"},{"key":"1035_CR76","doi-asserted-by":"publisher","first-page":"5404","DOI":"10.1007\/s00330-020-06929-z","volume":"30","author":"M de Rooij","year":"2020","unstructured":"de Rooij M, Isra\u00ebl B, Tummers M, Ahmed HU, Barrett T, Giganti F, et al. ESUR\/ESUI consensus statements on multi-parametric MRI for the detection of clinically significant prostate cancer: quality requirements for image acquisition, interpretation and radiologists\u2019 training. Eur Radiol. 2020;30:5404\u201316. https:\/\/doi.org\/10.1007\/s00330-020-06929-z","journal-title":"Eur Radiol [Internet]"},{"key":"1035_CR77","unstructured":"https:\/\/www.acr.org\/Accreditation\/Designations\/Prostate-Cancer-MRI-Center-Designation."},{"key":"1035_CR78","unstructured":"https:\/\/www.esur.org\/european-certification-in-prostate-mri\/."},{"key":"1035_CR79","unstructured":"https:\/\/www.acr.org\/Accreditation\/Modalities\/MRI."},{"key":"1035_CR80","doi-asserted-by":"publisher","first-page":"4013","DOI":"10.1007\/s00330-024-11322-1","volume":"35","author":"AR Padhani","year":"2024","unstructured":"Padhani AR, Woo S. Refining the need for prostate biopsy and the evolving role of MRI. Eur Radiol. 2024;35:4013\u20135. https:\/\/doi.org\/10.1007\/s00330-024-11322-1.","journal-title":"Eur Radiol"},{"key":"1035_CR81","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1001\/jamaoncol.2024.5497","volume":"11","author":"CA Hamm","year":"2025","unstructured":"Hamm CA, Asbach P, P\u00f6hlmann A, Schoots IG, Kasivisvanathan V, Henkel TO, et al. Oncological safety of MRI-informed biopsy decision-making in men with suspected prostate cancer. JAMA Oncol. 2025;11:145. https:\/\/doi.org\/10.1001\/jamaoncol.2024.5497.","journal-title":"JAMA Oncol"},{"key":"1035_CR82","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.eururo.2025.05.038","volume":"88","author":"IG Schoots","year":"2025","unstructured":"Schoots IG, Ahmed HU, Albers P, Asbach P, van den Bergh RCN, Godtman RA, et al. Magnetic resonance imaging\u2013based biopsy strategies in prostate cancer screening: a systematic review. Eur Urol. 2025;88:247\u201360. https:\/\/doi.org\/10.1016\/j.eururo.2025.05.038.","journal-title":"Eur Urol"},{"key":"1035_CR83","doi-asserted-by":"publisher","unstructured":"de Oliveira Correia ET, Purysko AS, Paranhos BM, Shoag JE, Padhani AR, Bittencourt LK. PI-RADS upgrading rules: impact on prostate cancer detection and biopsy avoidance of MRI-directed diagnostic pathways. AJR Am J Roentgenol. 2024;222. https:\/\/doi.org\/10.2214\/AJR.23.30611.","DOI":"10.2214\/AJR.23.30611"}],"container-title":["Cancer Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40644-026-01035-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40644-026-01035-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40644-026-01035-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T15:02:33Z","timestamp":1783609353000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40644-026-01035-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,18]]},"references-count":83,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1035"],"URL":"https:\/\/doi.org\/10.1186\/s40644-026-01035-7","relation":{"references":[{"id-type":"doi","id":"10.1016\/j.eururo.2015.08.052","asserted-by":"subject"},{"id-type":"doi","id":"10.1016\/j.eururo.2019.02.033","asserted-by":"subject"},{"id-type":"doi","id":"10.1102\/1470-7330.2011.9007","asserted-by":"subject"},{"id-type":"doi","id":"10.1016\/j.euo.2021.03.004","asserted-by":"subject"},{"id-type":"doi","id":"10.2214\/AJR.20.24495","asserted-by":"subject"}]},"ISSN":["1470-7330"],"issn-type":[{"value":"1470-7330","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,18]]},"assertion":[{"value":"14 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"IGS is co-chair of the ACR PI-RADS steering committee and a full panel member of the European Association of Urology prostate cancer guidelines. ARP is an advisor to Siemens Healthineers and Lucida Medical, and past co-chair of the ACR PI-RADS steering committee.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"86"}}